-DOCSTART- -X- O
Allogeneic -X- _ B-Intervention
stem -X- _ I-Intervention
cell -X- _ I-Intervention
transplant -X- _ I-Intervention
for -X- _ O
multiple -X- _ B-Patient
myeloma -X- _ I-Patient
( -X- _ I-Patient
MM -X- _ I-Patient
) -X- _ I-Patient
is -X- _ O
one -X- _ O
treatment -X- _ O
associated -X- _ O
with -X- _ O
long- -X- _ O
term -X- _ O
disease-free -X- _ O
survival. -X- _ O
The -X- _ O
high -X- _ O
incidence -X- _ O
of -X- _ O
treatment-related -X- _ O
mortality -X- _ O
and -X- _ O
relapses -X- _ O
, -X- _ O
however -X- _ O
, -X- _ O
are -X- _ O
important -X- _ O
reasons -X- _ O
for -X- _ O
controversy -X- _ O
about -X- _ O
the -X- _ O
role -X- _ O
of -X- _ O
allografting -X- _ B-Intervention
in -X- _ O
the -X- _ O
management -X- _ O
of -X- _ O
MM. -X- _ O
We -X- _ O
reviewed -X- _ O
our -X- _ O
results -X- _ O
of -X- _ O
allografting -X- _ O
for -X- _ O
MM -X- _ O
spanning -X- _ O
a -X- _ O
period -X- _ O
of -X- _ O
34 -X- _ O
years -X- _ O
in -X- _ O
order -X- _ O
to -X- _ O
better -X- _ O
define -X- _ O
long-term -X- _ O
outcomes -X- _ O
and -X- _ O
identify -X- _ O
areas -X- _ O
of -X- _ O
progress -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
areas -X- _ O
requiring -X- _ O
improvement. -X- _ O
A -X- _ O
total -X- _ O
of -X- _ O
278 -X- _ B-Patient
patients -X- _ I-Patient
received -X- _ O
allogeneic -X- _ B-Intervention
marrow -X- _ I-Intervention
or -X- _ I-Intervention
PBSCs -X- _ I-Intervention
after -X- _ I-Intervention
high-dose -X- _ I-Intervention
myeloablative -X- _ I-Intervention
( -X- _ I-Intervention
N=144 -X- _ I-Intervention
) -X- _ I-Intervention
or -X- _ I-Intervention
reduced -X- _ I-Intervention
intensity -X- _ I-Intervention
, -X- _ I-Intervention
non-myeloablative -X- _ I-Intervention
( -X- _ I-Intervention
N=134 -X- _ I-Intervention
) -X- _ I-Intervention
regimens. -X- _ I-Intervention
In -X- _ O
multivariable -X- _ O
analysis -X- _ O
, -X- _ O
adjusting -X- _ O
for -X- _ O
differences -X- _ O
in -X- _ O
patient -X- _ O
groups -X- _ O
, -X- _ O
reduced -X- _ B-Outcome
intensity -X- _ I-Outcome
/ -X- _ I-Outcome
non-myeloablative -X- _ I-Outcome
transplants -X- _ I-Outcome
were -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
significantly -X- _ I-Outcome
less -X- _ I-Outcome
acute -X- _ I-Outcome
GVHD -X- _ I-Outcome
, -X- _ I-Outcome
lower -X- _ I-Outcome
transplant -X- _ I-Outcome
mortality -X- _ I-Outcome
, -X- _ I-Outcome
better -X- _ I-Outcome
PFS -X- _ I-Outcome
and -X- _ I-Outcome
overall -X- _ I-Outcome
survival. -X- _ I-Outcome
There -X- _ I-Outcome
were -X- _ I-Outcome
no -X- _ I-Outcome
significant -X- _ I-Outcome
differences -X- _ I-Outcome
in -X- _ I-Outcome
relapse -X- _ I-Outcome
, -X- _ I-Outcome
progression -X- _ I-Outcome
or -X- _ I-Outcome
chronic -X- _ I-Outcome
GVHD -X- _ I-Outcome
, -X- _ I-Outcome
when -X- _ I-Outcome
adjusted. -X- _ I-Outcome
In -X- _ I-Outcome
multivariable -X- _ I-Outcome
analysis -X- _ I-Outcome
of -X- _ I-Outcome
patients -X- _ I-Outcome
receiving -X- _ I-Outcome
only -X- _ I-Outcome
non-myeloablative -X- _ I-Outcome
transplants -X- _ I-Outcome
, -X- _ I-Outcome
decreased -X- _ I-Outcome
overall -X- _ I-Outcome
survival -X- _ I-Outcome
and -X- _ I-Outcome
PFS -X- _ I-Outcome
were -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
relapse -X- _ I-Outcome
after -X- _ I-Outcome
a -X- _ I-Outcome
prior -X- _ I-Outcome
autograft -X- _ I-Outcome
and -X- _ I-Outcome
a -X- _ I-Outcome
Î²2 -X- _ I-Outcome
microglobulin -X- _ I-Outcome
> -X- _ I-Outcome
4.0. -X- _ I-Outcome
Transplant -X- _ I-Outcome
mortality -X- _ I-Outcome
was -X- _ I-Outcome
reduced -X- _ I-Outcome
and -X- _ I-Outcome
only -X- _ I-Outcome
influenced -X- _ I-Outcome
by -X- _ I-Outcome
a -X- _ I-Outcome
prior -X- _ I-Outcome
tandem -X- _ I-Outcome
autograft -X- _ I-Outcome
. -X- _ O

